Real-world walking cadence in people with COPD
- PMID: 38444656
- PMCID: PMC10910309
- DOI: 10.1183/23120541.00673-2023
Real-world walking cadence in people with COPD
Abstract
Introduction: The clinical validity of real-world walking cadence in people with COPD is unsettled. Our objective was to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence.
Methods: We assessed walking cadence (steps per minute during walking bouts longer than 10 s) from 7 days' accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during a 12-month follow-up were recorded from patient reports and medical registries.
Results: Participants were mostly male (80%) and had mean±sd age of 68±8 years, post-bronchodilator forced expiratory volume in 1 s (FEV1) of 57±19% predicted and walked 6880±3926 steps·day-1. Mean walking cadence was 88±9 steps·min-1, followed a normal distribution and was highly stable within-person (intraclass correlation coefficient 0.92, 95% CI 0.90-0.93). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV1, 6-min walk distance, physical activity (steps·day-1, time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (incidence rate ratio 0.94 per step·min-1, 95% CI 0.91-0.99, p=0.009).
Conclusions: Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as a future prognostic marker and clinical outcome.
Copyright ©The authors 2024.
Conflict of interest statement
Conflict of interest: N. Karlsson reports owning stock in AstraZeneca, of which they are an employee; discourse made outside the submitted work. Conflict of interest: L. Palmerini reports being the co-founder of mHealth Technologies srl and owns shares of mHealth Technologies srl; disclosures made outside the submitted work. Conflict of interest: M.I. Polkey reports receiving consulting fees from Philips Respironics, outside the submitted work. Conflict of interest: D.A. Rodríguez Chiaradia reports grants or contracts from Janssen and Ferrer; consulting fees from Ferrer; payments for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferrer and Janssen; support for attending meetings and/or travel from Ferrer, MSD and Janssen; and participation on a Data Safety Monitoring Board or Advisory Board for Janssen, all outside the submitted work. Conflict of interest: R. Rodriguez-Roisin reports grants or contracts from Chiesi and Beyond Air NO, outside the submitted work. Conflict of interest: I. Vogiatzis is an associate editor of this journal. Conflict of interest: T. Troosters reports grants or contracts from Mobilise-D IHI funding, outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose.
Figures
References
LinkOut - more resources
Full Text Sources
Miscellaneous